Squamous Cell Lung Cancer
Conditions
Interventions
one:anlotinib
two:Erlotinib + vinorelbine
three:vinorelbine
Sponsors
Anhui Chest Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18~80 years old, man or woman; 2. The pathological/cytology diagnosis of advanced squamous cell lung cancer patients,with measurable focus (the longest tumor diameter >=10mm, the smallest nodule >=15mm and the slice thickness =90 g/L; ANC>=1.5*10^9/L; PLT>=80*10^9/L; (2) TBIL 45 ml/min (Cockcroft-Gault formula); 7. women of childbearing age must have taken reliable contraceptive measures or 7 days before the group performed a pregnancy test (serum or urine), and the result is negative, and willing to experiment and during the last eight weeks after administration of the test drugs using appropriate methods contraception. For men shall be agreed to during the trial and after the last administration of the test drugs eight weeks using appropriate methods of contraception or sterilization surgery; 8. The subjects voluntarily joined the study, and informed consent, good compliance, with the follow-up.
Exclusion criteria
Exclusion criteria: 1. pregnant or lactating; 2. Has violated the pulmonary artery or hollow type lung squamous carcinoma; 3. Patients who are concurrently treated with radiotherapy; 4. After suffering from high blood pressure and antihypertensive medications can not fall within the normal range (systolic blood pressure> 140 mmHg, diastolic blood pressure> 90 mmHg) above the level of suffering I myocardial ischemia,myocardial infarction, arrhythmia or Class II cardiac sufficiency; 5. coagulation abnormalities (INR> 1.5 or APTT>1.5ULN + 4 seconds, or APTT>1.5 ULN), having bleeding tendency,or treated with thrombolysis and anticoagulation; 6. Patients with clear gastrointestinal bleeding concerns(including the following situations: local active ulcerative lesions, and defecate occult blood (++)); A period of 6 months prior to the start of the study gastrointestinal bleeding event has occurred; 7. Accompanied by the central nervous system transfer; 8. A period of 4 weeks prior to the start of taking the study drug, =CTCAE 2 pneumorrhagia or =CTCAE 3 other organs bleeding event has occurred; 9. Investigator judgment that may affect the conduct of clinical studies and case studies determined.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS; | — |
Countries
China
Contacts
Public ContactQingming Shi
Anhui Chest Hospital
Outcome results
None listed